Jim Simons
HOWL icon

Jim Simons’s Werewolf Therapeutics HOWL Stock Holding History

Jim Simons’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$430K Sell
516,218
-161,548
-24% -$111K ﹤0.01% 2664
2025
Q4 		$429K Buy
677,766
+221,766
+49% +$270K ﹤0.01% 2634
2025
Q3 		$898K Buy
456,000
+139,700
+44% +$191K ﹤0.01% 2542
2025
Q2 		$345K Buy
316,300
+252,400
+395% +$260K ﹤0.01% 2993
2025
Q1 		$62.1K Buy
63,900
+7,000
+12% +$9.17K ﹤0.01% 3266
2024
Q4 		$84.2K Sell
56,900
-95,300
-63% -$194K ﹤0.01% 3311
2024
Q3 		$323K Sell
152,200
-18,800
-11% -$42.8K ﹤0.01% 2955
2024
Q2 		$417K Buy
171,000
+86,800
+103% +$417K ﹤0.01% 2781
2024
Q1 		$546K Sell
84,200
-23,306
-22% -$136K ﹤0.01% 2823
2023
Q4 		$415K Buy
107,506
+62,306
+138% +$159K ﹤0.01% 2854
2023
Q3 		$97K Buy
45,200
+2,300
+5% +$6.34K ﹤0.01% 3254
2023
Q2 		$131K Buy
42,900
+8,800
+26% +$24.8K ﹤0.01% 3408
2023
Q1 		$89K Sell
34,100
-44,123
-56% -$132K ﹤0.01% 3525
2022
Q4 		$160K Buy
78,223
+59,923
+327% +$157K ﹤0.01% 3490
2022
Q3 		$83K Buy
18,300
+1,500
+9% +$8.14K ﹤0.01% 3650
2022
Q2 		$69K Buy
+16,800
New +$76.7K ﹤0.01% 3935

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jim Simons's HOWL Position: Q1 2026 in Review

Jim Simons reduced its Werewolf Therapeutics (HOWL) stake by 24% in Q1 2026, selling an estimated $111K and leaving 516,218 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Jim Simons first reported a position in HOWL in Q2 2022 and has held it in 16 quarters since. The position peaked at $898K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Jim Simons held 516,218 shares of Werewolf Therapeutics worth $430K as of Q1 2026.
  • Jim Simons sold 161,548 Werewolf Therapeutics shares in Q1 2026, an estimated $111K.
  • Werewolf Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2664 holding.
  • Jim Simons first reported a position in Werewolf Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Jim Simons's Werewolf Therapeutics position peaked at $898K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.